Avidity Biosciences Stock Analysis
RNA Stock | USD 33.44 2.60 8.43% |
Avidity Biosciences is undervalued with Real Value of 40.23 and Target Price of 68.27. The main objective of Avidity Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Avidity Biosciences is worth, separate from its market price. There are two main types of Avidity Biosciences' stock analysis: fundamental analysis and technical analysis.
The Avidity Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Avidity Biosciences' ongoing operational relationships across important fundamental and technical indicators.
Avidity |
Avidity Stock Analysis Notes
About 95.0% of the company shares are owned by institutional investors. The book value of Avidity Biosciences was at this time reported as 11.89. The company recorded a loss per share of 2.89. Avidity Biosciences had not issued any dividends in recent years. Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Avidity Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 125 people. To find out more about Avidity Biosciences contact Sarah Boyce at 858 401 7900 or learn more at https://www.aviditybiosciences.com.Avidity Biosciences Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Avidity Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Avidity Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Avidity Biosciences had very high historical volatility over the last 90 days | |
The company reported the last year's revenue of 10.9 M. Reported Net Loss for the year was (322.3 M) with loss before taxes, overhead, and interest of (292.7 M). | |
Avidity Biosciences has about 398.22 M in cash with (300.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
Avidity Biosciences has a poor financial position based on the latest SEC disclosures | |
Over 95.0% of the company shares are owned by institutional investors | |
Latest headline from thelincolnianonline.com: Disposition of 7778 shares by Teresa McCarthy of Avidity Biosciences at 31.0598 subject to Rule 16b-3 |
Avidity Biosciences Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avidity Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of February 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Avidity Largest EPS Surprises
Earnings surprises can significantly impact Avidity Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2014-06-30 | 2014-06-30 | -0.25 | -0.22 | 0.03 | 12 | ||
2020-11-10 | 2020-09-30 | -0.37 | -0.31 | 0.06 | 16 | ||
2014-09-30 | 2014-09-30 | -0.23 | -0.29 | -0.06 | 26 |
Avidity Biosciences Environmental, Social, and Governance (ESG) Scores
Avidity Biosciences' ESG score is a quantitative measure that evaluates Avidity Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Avidity Biosciences' operations that may have significant financial implications and affect Avidity Biosciences' stock price as well as guide investors towards more socially responsible investments.
Avidity Stock Institutional Investors
Shares | Td Asset Management Inc | 2024-12-31 | 415.2 K |
Avidity Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.71 B.Avidity Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.21) | (0.22) | |
Return On Capital Employed | (0.26) | (0.25) | |
Return On Assets | (0.21) | (0.22) | |
Return On Equity | (0.23) | (0.21) |
Management Efficiency
Avidity Biosciences has Return on Asset of (0.2161) % which means that on every $100 spent on assets, it lost $0.2161. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3347) %, meaning that it generated no profit with money invested by stockholders. Avidity Biosciences' management efficiency ratios could be used to measure how well Avidity Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 24, 2025, Return On Tangible Assets is expected to decline to -0.22. The current year's Return On Capital Employed is expected to grow to -0.25. At present, Avidity Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 42.8 M, whereas Other Assets are forecasted to decline to 0.86.Last Reported | Projected for Next Year | ||
Book Value Per Share | 12.77 | 13.41 | |
Tangible Book Value Per Share | 12.77 | 13.41 | |
Enterprise Value Over EBITDA | (8.00) | (8.40) | |
Price Book Value Ratio | 2.28 | 2.39 | |
Enterprise Value Multiple | (8.00) | (8.40) | |
Price Fair Value | 2.28 | 2.39 | |
Enterprise Value | 537 M | 477.3 M |
Leadership effectiveness at Avidity Biosciences is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 24th of March, Avidity Biosciences shows the Risk Adjusted Performance of 0.004, mean deviation of 2.83, and Standard Deviation of 3.63. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Avidity Biosciences, as well as the relationship between them.Avidity Biosciences Price Movement Analysis
The output start index for this execution was four with a total number of output elements of fifty-seven. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Avidity Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Avidity Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Avidity Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avidity Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avidity Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avidity Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avidity Biosciences Outstanding Bonds
Avidity Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avidity Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avidity bonds can be classified according to their maturity, which is the date when Avidity Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Avis Budget Car Corp BondUS053773BC09 | View | |
AVIS BUDGET CAR Corp BondUS053773BE64 | View | |
AVA 4 01 APR 52 Corp BondUS05379BAR87 | View | |
AVISTA P 435 Corp BondUS05379BAQ05 | View | |
US053773BF30 Corp BondUS053773BF30 | View | |
US053773BG13 Corp BondUS053773BG13 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Avidity Biosciences Predictive Daily Indicators
Avidity Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Avidity Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Avidity Biosciences Corporate Filings
F4 | 21st of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 4th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
14th of February 2025 Other Reports | ViewVerify | |
F4 | 5th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 23rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Avidity Biosciences Forecast Models
Avidity Biosciences' time-series forecasting models are one of many Avidity Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Avidity Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Avidity Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Avidity Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Avidity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Avidity Biosciences. By using and applying Avidity Stock analysis, traders can create a robust methodology for identifying Avidity entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (29.58) | (31.06) | |
Operating Profit Margin | (34.77) | (36.51) | |
Net Loss | (29.58) | (31.06) | |
Gross Profit Margin | 0.70 | 0.74 |
Current Avidity Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Avidity analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Avidity analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
68.27 | Strong Buy | 11 | Odds |
Most Avidity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Avidity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Avidity Biosciences, talking to its executives and customers, or listening to Avidity conference calls.
Avidity Stock Analysis Indicators
Avidity Biosciences stock analysis indicators help investors evaluate how Avidity Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Avidity Biosciences shares will generate the highest return on investment. By understating and applying Avidity Biosciences stock analysis, traders can identify Avidity Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 185.4 M | |
Common Stock Shares Outstanding | 111.6 M | |
Total Stockholder Equity | 1.4 B | |
Property Plant And Equipment Net | 18.3 M | |
Cash And Short Term Investments | 1.5 B | |
Cash | 219.9 M | |
Accounts Payable | 8.5 M | |
Net Debt | -213.1 M | |
50 Day M A | 31.0734 | |
Total Current Liabilities | 98 M | |
Other Operating Expenses | 389.8 M | |
Non Current Assets Total | 21.6 M | |
Non Currrent Assets Other | 3.3 M | |
Stock Based Compensation | 51.4 M |
Complementary Tools for Avidity Stock analysis
When running Avidity Biosciences' price analysis, check to measure Avidity Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avidity Biosciences is operating at the current time. Most of Avidity Biosciences' value examination focuses on studying past and present price action to predict the probability of Avidity Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avidity Biosciences' price. Additionally, you may evaluate how the addition of Avidity Biosciences to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |